We are currently recruiting participants for a new medical research study that is looking at a potential new combination vaccine for COVID-19 and flu.
This is a study of an experimental vaccine against SARS-CoV-2, the virus that causes COVID-19 disease and seasonal influenza (“flu”) virus. This experimental vaccine is a combination of two individual experimental vaccines, one vaccine against flu and one vaccine against SARS-CoV-2.
The Sponsor is developing a combination vaccine that aims to prevent serious illness or infection of both the flu virus and SARS-CoV-2 virus in people who are at least 65 or more years old.
Phase 3 Study of the Safety and Immunogenicity of a COVID-19 and Influenza Combination Vaccine and a Standalone Nanoparticle Influenza Vaccine in Participants ≥ 65 years of Age
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
- Registry listing
-
ERM Project ID
107992
Trial contact details
-
Contact person
RIO Clinical Trials Unit
-
Phone
07 3163 1369
What you need to know
Who can take part
Inclusion Criteria:
- You have completed at least one vaccination series against SARS-CoV-2 (the virus that causes COVID-19) with an approved COVID-19 vaccine;
- Your second or last COVID-19 vaccine dose was more than 8 weeks ago;
- You are considered medically stable based on history and physical examination by a qualified medical doctor at this site.
What is involved for me?
- Informed Consent
- Collection of medical history, medication and previous vaccinations
- Physical examination, Vitals signs, ECG
- Blood tests and mucosal sample collection
- Diary entry for 7 days to record any vaccine reactions.
